Article Information
History
- September 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Layla Mathieson1,2,#,
- Lilian Koppensteiner1,2,
- Samuel Pattle3,
- David A Dorward1,3,
- Richard O’Connor1,2 and
- Ahsan Akram1,2,4,#
- 1Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh BioQuarter, Edinburgh, United Kingdom, EH16 4TJ
- 2Translational Healthcare Technologies Group, Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh BioQuarter, Edinburgh, United Kingdom, EH16 4TJ
- 3Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, EH16 4SA
- 4Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Crewe Road South, Edinburgh, United Kingdom, EH4 2XR
- ↵#Correspondence to: Layla Mathieson (L.Mathieson-1{at}sms.ed.ac.uk) or Ahsan Akram (ahsan.akram{at}ed.ac.uk)
Posted September 30, 2022.
Subpopulations of cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer are a predictor of poor clinical outcome
